Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Hilden

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
European Urology Oncology|August 19, 2022
Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
European Urology Oncology|May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
Surgery|May 17, 2020
Disparities in utilization of services for racial and ethnic minorities with hepatocellular carcinoma associated with hepatitis CAaron Kangas-Dick, Victor Gall, Patrick Hilden, et al.
Cell Reports|August 23, 2018
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K InhibitorsEnrico Derenzini, Patrizia Mondello, Tatiana Erazo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 12, 2016
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung AdenocarcinomasM C Pietanza, Matthew D Hellmann, John J Fiore, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 24, 2017
T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic MalignanciesAnn A Jakubowski, Erica Petrlik, Molly Maloy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 29, 2018
Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell TransplantationCarlos Rondon-Clavo, Michael Scordo, Patrick Hilden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate EvaluationMichael L Maitland, Julia Wilkerson, Sanja Karovic, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2019
Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host DiseaseJuan Montoro, Izaskun Ceberio, Patrick Hilden, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2019
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34<sup>+</sup> Selected Allogeneic Hematopoietic Cell TransplantationMichael Scordo, Valkal Bhatt, Patrick Hilden, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
European Urology Oncology|August 19, 2022
Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
European Urology Oncology|May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
Surgery|May 17, 2020
Disparities in utilization of services for racial and ethnic minorities with hepatocellular carcinoma associated with hepatitis CAaron Kangas-Dick, Victor Gall, Patrick Hilden, et al.
Cell Reports|August 23, 2018
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K InhibitorsEnrico Derenzini, Patrizia Mondello, Tatiana Erazo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 12, 2016
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung AdenocarcinomasM C Pietanza, Matthew D Hellmann, John J Fiore, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 24, 2017
T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic MalignanciesAnn A Jakubowski, Erica Petrlik, Molly Maloy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 29, 2018
Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell TransplantationCarlos Rondon-Clavo, Michael Scordo, Patrick Hilden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate EvaluationMichael L Maitland, Julia Wilkerson, Sanja Karovic, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2019
Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host DiseaseJuan Montoro, Izaskun Ceberio, Patrick Hilden, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2019
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34<sup>+</sup> Selected Allogeneic Hematopoietic Cell TransplantationMichael Scordo, Valkal Bhatt, Patrick Hilden, et al.
Pageof 5